https://www.selleckchem.com/products/r428.html
Transcatheter Arterial chemoembolization (TACE) is the first-line option for the intermediate-stage hepatocellular carcinoma. Guidelines do not define the number of TACE sessions to be repeated before stopping treatment and switching to sorafenib. We retrospectively analysed 76 patients aged ≥65years who were treated by multiple TACE sessions (re-TACE group; N=36 patients) or one TACE session followed by sorafenib (TACE/Sorafenib group; N=40 patients). The primary outcome was the overall survival (Kaplan-Meier analysis and log-rank test).
Like
Comment
Share
